An interventional study of Intense Pulsed Light Treatment (IPL) and Meibomian Gland Expression in Ocular Rosacea and Dry Eye, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-01-03.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Dry eye disease (DED) is a common condition that causes ocular discomfort and reduces visual acuity. The two categories of DED are evaporative dry eye and aqueous deficient dry eye. Both conditions can involve pathology of the meibomian glands, lacrimal glands, lids, tear film and surface cells. Meibomian gland dysfunction (MGD) is the leading cause of evaporative dry eye and contributes to aqueous deficient dry eye. The goal of MGD therapy is to provide long term improvement of symptoms for patients by improving the quality of meibum, increasing meibum flow, improving tear film stability and decreasing inflammation.
Commonly used therapies include preservative free drops, omega-3 fatty acid supplementation, topical cyclosporine, serum tears, topical azithromycin, oral doxycycline, moisture chambers, intraductal probing, lib margin exfoliation, automated thermal pulsation, warm compresses, among other. Despite this variety of symptoms, patients often do not experience complete or long term relief of symptoms.
Forced meibomian gland expression (MGX) has been shown to be an effective method of rehabilitating meibomian glands and improving dry eye symptoms. The eyelid margins are forcefully compressed to express gland contents. Research has shown improvement in patient symptoms with the use of MGX.
Intense pulsed light (IPL) have been used in dermatology to treat various conditions. Patients with DED who have tried other therapies and found no relief, often resort to IPL as a last resort. Research has shown IPL alone may be effective in improving patient symptoms. In addition, such studies have failed to show significant adverse events with the use of IPL.
Here, we propose a prospective, randomized, case controlled clinical pilot study to examine the efficacy for both subjective and objective measures. 20 patients with DED will be recruited and will be randomly assigned to one of two groups: MGX alone or MGX with IPL. Objective measures will include tear cytokine levels, impression cytology, meibography, tear osmolarity and others. Subjective measures will include quality of life screening tools.
We hypothesize that the use of MGX with IPL will lead to greater improvement in subjective dry eye symptoms and objective measures. Given the lack of adverse effects reported in the literature, we do not anticipate adverse effects in our study.
Rochester staff Drs. Faustch and Bourne are providing clinical research advice but have no contact with subjects or biospecimens.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 192 are open to participants now.
This study's enrollment of 20 is below the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Dry eye of moderate severity with ocular rosacea diagnosed by ophthalmologist. No contraindications of severe ocular surface disease or inability to be safely treated with IPL.
Dry eye symptoms must be alleviated with topical anesthetic. No GVHD, Stevens Johnson, active allergic conjunctivitis or other conjunctivitis, alkali burn history.
Subjects must have at least 50% meibomian glands viable on meibography and no new treatments for dry eye in the past 6 months.
Contact lenses and refractive surgery is okay.
Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
Device: Intense Pulsed Light Treatment (IPL) · Procedure: Meibomian Gland Expression
Treatment with 4 visits and 4 treatments of MGX only
Procedure: Meibomian Gland Expression
IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score
Symptom survey on severity of dry eye symptoms. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.
Time frame: baseline, 3 months
Change in Meibomian Glands Open - Right Lower Lid
The count of manual expression of the meibomian glands. A thumb is placed against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
Time frame: baseline, 3 months
Change in Meibomian Glands Open - Left Lower Lid
The count of manual expression of the meibomian glands. A thumb is placed against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
Time frame: 3 months
| Milestone | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Symptom survey on severity of dry eye symptoms. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.
| percentage of change in OSDI score | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) |
|---|---|---|
| Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score | -25.9 ± 20.0 | -2.0 ± 17.9 |
The count of manual expression of the meibomian glands. A thumb is placed against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
| percentage of blocked meibomian pores | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) |
|---|---|---|
| Change in Meibomian Glands Open - Right Lower Lid | 6.9 ± 11.0 | 5.0 ± 11.0 |
The count of manual expression of the meibomian glands. A thumb is placed against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
| percentage of blocked meibomian | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) |
|---|---|---|
| Change in Meibomian Glands Open - Left Lower Lid | 14.4 ± 16.1 | 10.0 ± 14.1 |
Collected over Adverse Events were collected over a period of 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MGX and Intense Pulsed Light Treatment (IPL) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Meibomian Gland Expression (MGX) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Age, Continuous(years) | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) | Total |
|---|---|---|---|
| Mean | 59.3 ± 11.7 | 60.5 ± 12.1 | 59.9 ± 11.6 |
| Sex: Female, Male(Participants) | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) | Total |
|---|---|---|---|
| Female | 7 | 10 | 17 |
| Male | 3 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) | Total |
|---|---|---|---|
| Hispanic/Latino | 0 | 1 | 1 |
| Not Disclosed | 1 | 0 | 1 |
| White | 9 | 9 | 18 |
| Region of Enrollment(participants) | MGX and Intense Pulsed Light Treatment (IPL) | Meibomian Gland Expression (MGX) | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic